📰 Disease Modification News

Disease Modification News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Disease Modification. Real-time updates on events, politics, business and more.

Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson's Disease with its NLRP3 Inhibitor, Dapansutrile

February 20, 2024

Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson&#039;s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow...

United Kingdom City Of Damaris Skouras Queen Square Caroline Williams Gray Carolineh Williams Gray

Source: lelezard.com

Neuroprotective Agents Market is set to Reach US$ 143.78

February 19, 2024

Pune, Feb. 19, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Neuroprotective Agents Market is...

United States Asia Pacific Premium Research A Sample Copy Of The Research Customer Base Assessment Strategic Development

Source: globenewswire.com

Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES

December 2, 2021

Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome...

United States Porter Novelli Trish Mccall Tevard Biosciences Bradleys Galer Brian Ritchie

Source: globenewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Disease Modification News Today

Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson's Disease with its NLRP3 Inhibitor, Dapansutrile

Neuroprotective Agents Market is set to Reach US$ 143.78

Zogenix To Present New FINTEPLA&#xAE; (fenfluramine) Data at AES

Explore More Categories

Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES